Risk of vascular access thrombosis in patients with systemic lupus erythematosus on hemodialysis

Journal of Vascular Access

Volumn 8, Issue 2, 2007, Pages 103-108

  Shafi, Salman Tahir ^a,c   Gupta, M ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c NONE   (United States)

Author keywords

Hemodiaysis; Systemic lupus erythematosus; Thrombosis; Vascular access

Indexed keywords

CARDIOLIPIN ANTIBODY;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTERIOVENOUS SHUNT; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE PREDISPOSITION; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HIGH RISK POPULATION; HUMAN; KIDNEY FAILURE; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SHUNT THROMBOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOGENESIS; VASCULAR ACCESS;

EID: 34447303314     PISSN: 11297298     EISSN: None     Source Type: Journal    
DOI: 10.1177/112972980700800207     Document Type: Article

References (31)

1. Fan PY, Schwab SJ. Vascular access: Concepts for the 1990s. J Am Soc Nephrol 1992; 3: 1-11.
2. Feldman HI, Held PJ, Hutchinson JT, et al. Hemodialysis vascular access morbidity in the United States. Kidney Int 1993; 43: 1091-6.
3. Besarab A, Bolton WK, Browne JK, et al. The effects of normal as compared to low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-90.
4. Knoll GA, Wells PS, Young D, et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005; 16: 1108-14.
5. Asif A, Gadalean FN, Merrill D, et al. Inflow stenosis in arteriovenous fistulas and grafts: A multicenter, prospective study. Kidney Int 2005; 67: 1986-92.
6. Duijm LE, Liem YS, van der Rijt RH, et al. Inflow stenoses in dysfunctional hemodialysis access fistulae and grafts. Am J Kidney Dis 2006; 48: 98-105.
7. Schwab SJ. Vascular access for hemodialysis. Kidney Int 1999; 55: 2078-90.
8. Sands JJ, Nudo SA, Ashford RG, et al. Antibodies to topical bovine thrombin correlate with access thrombosis. Am J Kidney Dis 2000; 35: 796-801.
9. Brunet P, Aillaud MF, San Marco M, et al. Antiphospholipids in hemodialysis patients: relationship between lupus anticoagulant and thrombosis. Kidney Int 1995; 48: 794-800.
10. Garcia-Martin F, De Arriba G, Carrascosa T, et al. Anticariolipin antibodies and lupus anticoagulant in end stage renal disease. Nephrol Dial Transplant 1991; 6: 543-7.
11. Prakash R, Miller CC 3rd, Suki WN. Anticardiolipin antibody in patients on maintenance hemodialysis and its association with recurrent arteriovenous graft thrombosis. Am J Kidney Dis 1995; 26: 347-52.
12. Haviv YS. Association of anticardiolipin antibodies with vascular access occlusion in hemodialysis patients: cause or effect? Nephron 2000; 86: 447-54.
13. Alder S, Szczech L, Qureshi A, Bollu R, Thomas-John R. IgM anicardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001; 56: 428-34.
14. Prieto LN, Suki WN. Frequent hemodialysis graft thrombosis; association with antiphospholipid antibodies. Am J Kidney Dis 1994; 23: 587-90.
15. Love PE, Santore SA. Antiphospholipid antibodies: Anticardiolipin and lupus anticoagulant in systemic lupus erythrematosus (SLE) and non SLE disorders. Ann Intern Med 1990; 112: 682-98.
16. Palder SB, Kirkman RL, Whittemore AD, et al. Vascular access for hemodialysis. Ann Surg 1985; 202: 235-9.
17. Munda R, First MR, Alexander JW, et al. PTFE graft survival in hemodialysis. JAMA 1983; 249: 219-22.
18. White RH, Zhou H, Murin S et al. Effect of ethnicity and gender on the incidence of venous thromboembolism in a diverse population in California in 1996. Thromb Haemost 2005; 93: 298-305.
19. Calvo-Alen J, Toloza SM, Fernandez M, et. al. Systemic lupus erythernatosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients. Arthritis Rheum 2005; 52: 2060-8.
20. Wahl DG, Guillemin F, de Maistre E. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus - a meta-analysis. Lupus 1997; 6: 467-73.
21. Sitter T, Spamagl M, Schiffl H. Anticardiolipin antibodies and lupus anticoagulants in patients treated with different methods of renal replacement therapy in comparison to patients with systemic lupus erythematosus. Ann Hematol 1992; 65: 79-82.
22. Cockwell P, Tse WY, Savage CO. Activation of endothelial cells in thrombosis and vasculitis. Scand J Rheumatol 1997; 26:145-50.
23. Takeya H, Tanaka Y, Suzuki K. Thrombosis and apoptosis. Jpn J Clin Pathol 1997; 45: 614-20.
24. Vaarala O, Alfthan G, Jauhiainen M. Cross-reaction between antibodies to oxidized LDL and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5.
25. Manns BJ, Burgess ED, Parsons HG, Schaefer JP, Hyndman ME, Scott-Douglas NW. Hyperhomocysteinemia, anticardiolipin antibody status, and risk for vascular access thrombosis in hemodialysis patients. Kidney Int 1999; 55: 315-20.
26. Chew SL, Lins RL, Daelemans R, Zachee P, De Clerck LS, Vermylen J. Are antiphospholipid antibodies clinically relevant in dialysis patients? Nephrol Dial Transplant 1992; 7; 1194-8.
27. Domoto DT, Bauman JE, Joist JH. Combined aspirin and sulfinpyrazone in the prevention of recurrent hemodialysis vascular access thrombosis. Thromb Res 1991; 62: 737-43.
28. Kaufman JS, O'Connor TZ, Zhang JH, Cronin RE. Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 2003; 14: 2313-21.
29. Crowther MA, Clase CM, Margetts PJ, et al. Low-intensity warfarin is ineffective for the prevention of PTFE graft failure in patients on hemodialysis: A randomized controlled trial. J Am Soc Nephrol 2002; 13: 2331-7.
30. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-7.
31. Vianna JL, Khamashta MA, Ordi-Ros J, et al. Comparison of the primary and secondary antiphospholipid syndrome: A European multicenter study of 114 patients. Am J Med 1994; 96: 3-9.